Clinical trial
Chemotherapy in Treating Patients With Newly Diagnosed Acute or Chronic…
NCT00002800 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00002800 |
|---|---|
| Title | Chemotherapy in Treating Patients With Newly Diagnosed Acute or Chronic Myelogenous Leukemia or Myelodysplastic Syndrome |
| Official title | PHASE II STUDY OF HIGH DOSE CYTARABINE COMBINED WITH A SINGLE HIGH DOSE OF IDARUBICIN FOR NEWLY DIAGNOSED PATIENTS WITH AML: THE AML-3 PROTOCOL |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia, Myelodysplastic Syndromes, Neutropenia |
| Intervention type | Biological, Drug |
| Interventions | filgrastim, lintuzumab, cytarabine, etoposide, idarubicin |
| Enrollment | 60 |
| Start date | Jul 1, 1996 |
| Primary completion | Mar 1, 2003 |
| Completion | Mar 1, 2003 |
| First posted | Apr 22, 2004 |
| Last update posted | Jul 3, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: